Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522206 | 1.00 | MAPK14 (0.46) | MAPK14DAPK1RECQLMAPK10SMN1; SMN2 | |
| SCHEMBL3523400 | 0.88 | MMP13 (0.50) | MAPK14DAPK1RECQLMAPK10SMN1; SMN2 | |
| SCHEMBL3520672 | 0.86 | MAPK14 (0.51) | MAPK14DAPK1RECQLMAPK10SMN1; SMN2 | |
| SCHEMBL3524527 | 0.85 | MAPK14 (0.60) | MAPK14DAPK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3522176 | 0.83 | MAPK14 (0.53) | MAPK14DAPK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3522304 | 0.83 | MAPK14 (0.55) | MAPK14DAPK1LMNAALDH1A1TSHR | |
| SCHEMBL3522825 | 0.82 | MAPK14 (0.54) | MAPK14DAPK1SMN1; SMN2SCDLMNA | |
| SCHEMBL3524246 | 0.82 | MAPK14 (0.54) | MAPK14DAPK1SMN1; SMN2SCDLMNA | |
| SCHEMBL3522210 | 0.82 | MAPK14 (0.47) | MAPK14DAPK1RECQLMAPK10SMN1; SMN2 | |
| SCHEMBL4376172 | 0.82 | MAPK14 (0.72) | MAPK14SMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885DAPK1 553/4885RECQL 721/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885DAPK1 682/4885RECQL 1164/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885DAPK1 553/4885RECQL 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.